Patents Assigned to Abiogen Pharma S.p.A.
-
Publication number: 20230233585Abstract: The use of neridronic acid or a salt thereof in the treatment of osteoarthritis is described. In particular, neridronic acid or a salt thereof has been shown to be able to reduce significantly the symptoms of osteoarthritis, such as pain and physical and mobility disabilities, as well as subchondral bone marrow lesions underlying the onset of such symptoms.Type: ApplicationFiled: March 29, 2023Publication date: July 27, 2023Applicant: ABIOGEN PHARMA S.P.A.Inventor: Massimo Varenna
-
Publication number: 20230082870Abstract: The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation.Type: ApplicationFiled: October 25, 2022Publication date: March 16, 2023Applicant: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Patrizia Chetoni, Silvia Tampucci
-
Patent number: 11512104Abstract: The present invention relates to a new process for the preparation of the crystalline polymorph of sodium neridronate in form hemihydrate F, comprising the following steps: a) reacting the 6-aminohexanoic acid with a mixture of phosphorous acid and methanesulfonic acid at a temperature in the range from 60 to 80° C., under stirring, until a clear solution is obtained; b) adding phosphorus trichloride to said solution of step (a) under stirring at a temperature in the range of 60 to 80° C.; c) diluting with water the reaction mixture obtained from the previous step (b) and heating said water diluted mixture at a temperature in the range from 80 to 120° C.; d) cooling the heated mixture obtained in step (c) up to room temperature, diluting it with water, then slowly adding an aqueous sodium hydroxide solution up to a pH in the range from 4.2 to 4.6, to obtain a neutralized solution; e) bringing the neutralized solution of step (d) up to a temperature of about 70° C.Type: GrantFiled: June 5, 2020Date of Patent: November 29, 2022Assignee: ABIOGEN PHARMA S.P.A.Inventors: Fabio Neggiani, Stefano Luca Giaffreda, Serena Fabbroni, Michel Chiarucci, Barbara Politi
-
Publication number: 20220273676Abstract: The use of cholecalciferol is described as an active agent in the treatment of celiac disease, in the reduction of intestinal villous atrophy, and in the protection and regeneration of the intestinal epithelium. Also described are pharmaceutical compositions or food supplements, as well as foods for celiacs, including cholecalciferol and suitable excipients for use in the treatment of celiac disease, in the reduction of intestinal villous atrophy and in the protection and regeneration of the intestinal epithelium.Type: ApplicationFiled: August 3, 2020Publication date: September 1, 2022Applicant: ABIOGEN PHARMA S.P.A.Inventor: Silvia Trasciatti
-
Publication number: 20220267359Abstract: The present invention relates to a new process for the preparation of the crystalline polymorph of sodium neridronate in form hemihydrate F, comprising the following steps: a) reacting the 6-aminohexanoic acid with a mixture of phosphorous acid and methanesulfonic acid at a temperature in the range from 60 to 80° C., under stirring, until a clear solution is obtained; b) adding rl phosphorus trichloride to said solution of step (a) under stirring at a temperature in the range of 60 to 80° C.; c) diluting with water the reaction mixture obtained from the previous step (b) and heating said water diluted mixture at a temperature in the range from 80 to 120° C.; d) cooling the heated mixture obtained in step (c) up to room temperature, diluting it with water, then slowly adding an aqueous sodium hydroxide solution up to a pH in the range from 4.2 to 4.6, to obtain a neutralized solution; e) bringing the neutralized solution of step (d) up to a temperature of about 70° C.Type: ApplicationFiled: June 5, 2020Publication date: August 25, 2022Applicant: ABIOGEN PHARMA S.P.A.Inventors: Fabio Neggiani, Stefano Luca Giaffreda, Serena Fabbroni, Michel Chiarucci, Barbara Politi
-
Patent number: 11123354Abstract: The present invention relates to a composition for use in the treatment of osteoarthritis (OA), wherein said composition comprises from 5 to 40 mg of sodium chlodronate, or an equivalent amount of chlodronic acid, or other pharmaceutically acceptable salts thereof, and wherein said composition is administered intra-articularly in a unitary dosage form once monthly, once biweekly or once weekly. Single-dose medicaments and kits comprising them are also described.Type: GrantFiled: December 6, 2017Date of Patent: September 21, 2021Assignee: ABIOGEN PHARMA S.P.A.Inventors: Fabio Neggiani, Silvia Trasciatti
-
Patent number: 11058138Abstract: The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation.Type: GrantFiled: September 6, 2018Date of Patent: July 13, 2021Assignee: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Samuele Zanatta
-
Publication number: 20200375897Abstract: The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation.Type: ApplicationFiled: September 6, 2018Publication date: December 3, 2020Applicant: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Patrizia Chetoni, Silvia Tampucci
-
Publication number: 20200375238Abstract: The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation.Type: ApplicationFiled: September 6, 2018Publication date: December 3, 2020Applicant: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Samuele Zanatta
-
Patent number: 10815257Abstract: The present invention relates to a novel crystalline hemihydrate polymorph of neridronic acid sodium salt, and a novel process for the preparation thereof comprising the steps of: 1) dissolving solid sodium neridronate in any crystalline form in water, at a temperature in the range from 70 to 90° C., to obtain an aqueous solution of sodium neridronate; 2) adding a solvent selected from the group consisting in ethanol, 1-propanol, and 2-propanol to the aqueous solution obtained from step (1), so that the final water:solvent volume ratio is in the range from 1:0.5 to 1:1, thus obtaining a suspension; 3) placing the suspension obtained from step (2) under mechanical stirring, at a temperature in the range from 60 to 95° C.; 4) recovering the crystalline hemihydrate form F of sodium neridronate formed in the previous step (3).Type: GrantFiled: April 10, 2019Date of Patent: October 27, 2020Assignee: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Barbara Politi, Stefano Luca Giaffreda, Alex Petrolati, Michel Chiarucci, Serena Fabbroni, Kesheng Zhang, Michael Roeder
-
Patent number: 10736856Abstract: The use of xibornol as a virucidal agent is described in the prophylactic or therapeutic treatment of an infection caused by one or more viruses, said viruses comprising at least one of human Adenovirus, human Rhinovirus, human Coronavirus, and a combination thereof.Type: GrantFiled: July 13, 2017Date of Patent: August 11, 2020Assignee: ABIOGEN PHARMA S.P.A.Inventor: Cristina Bigini
-
Publication number: 20200155478Abstract: The use of xibornol as an active agent in the treatment of Acne vulgaris is disclosed, said xibornol having shown a remarkable bacteriostatic and bactericidal action on the bacterium mainly responsible of the onset and worsening of Acne vulgaris, i.e. the bacterium Propionibacterium acnes. Pharmaceutical or cosmetic compositions comprising xibornol and suitable pharmaceutically or cosmetically acceptable excipients, for use in the treatment of Acne vulgaris are also disclosed.Type: ApplicationFiled: May 30, 2018Publication date: May 21, 2020Applicant: ABIOGEN PHARMA S.P.A.Inventor: Silvia Trasciatti
-
Publication number: 20200147126Abstract: Disclosed are pharmaceutical compositions containing clodronic acid and hyaluronic acid or their salts as active constituents, mixed with suitable vehicles.Type: ApplicationFiled: December 27, 2019Publication date: May 14, 2020Applicant: ABIOGEN PHARMA S.P.A.Inventors: Sergio ROSINI, Silvia Trasciatti
-
Publication number: 20200061088Abstract: The present invention relates to a composition for use in the treatment of osteoarthritis (OA), wherein said composition comprises from 5 to 40 mg of sodium chlodronate, or an equivalent amount of chlodronic acid, or other pharmaceutically acceptable salts thereof, and wherein said composition is administered intra-articularly in a unitary dosage form once monthly, once biweekly or once weekly. Single-dose medicaments and kits comprising them are also described.Type: ApplicationFiled: December 6, 2017Publication date: February 27, 2020Applicant: ABIOGEN PHARMA S.P.A.Inventors: Fabio Neggiani, Silvia Trasciatti
-
Publication number: 20190336456Abstract: The use of xibornol as a virucidal agent is described in the prophylactic or therapeutic treatment of an infection caused by one or more viruses, said viruses comprising at least one of human Adenovirus, human Rhinovirus, human Coronavirus, and a combination thereof.Type: ApplicationFiled: July 13, 2017Publication date: November 7, 2019Applicant: ABIOGEN PHARMA S.P.A.Inventor: Cristina Bigini
-
Publication number: 20190308999Abstract: The present invention relates to a novel crystalline hemihydrate polymorph of neridronic acid sodium salt, and a novel process for the preparation thereof comprising the steps of: 1) dissolving solid sodium neridronate in any crystalline form in water, at a temperature in the range from 70 to 90° C., to obtain an aqueous solution of sodium neridronate; 2) adding a solvent selected from the group consisting in ethanol, 1-propanol, and 2-propanol to the aqueous solution obtained from step (1), so that the final water:solvent volume ratio is in the range from 1:0.5 to 1:1, thus obtaining a suspension; 3) placing the suspension obtained from step (2) under mechanical stirring, at a temperature in the range from 60 to 95° C.; 4) recovering the crystalline hemihydrate form F of sodium neridronate formed in the previous step (3).Type: ApplicationFiled: April 10, 2019Publication date: October 10, 2019Applicant: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Barbara Politi, Stefano Luca Giaffreda, Alex Petrolati, Michel Chiarucci, Serena Fabbroni, Kesheng Zhang, Michael Roeder
-
Publication number: 20180185407Abstract: Disclosed are pharmaceutical compositions containing clodronic acid and hyaluronic acid or their salts as active constituents, mixed with suitable vehicles.Type: ApplicationFiled: February 28, 2018Publication date: July 5, 2018Applicant: ABIOGEN PHARMA S.P.A.Inventors: Sergio ROSINI, Silvia TRASCIATTI
-
Patent number: 9943540Abstract: Disclosed are pharmaceutical compositions containing clodronic acid and hyaluronic acid or their salts as active constituents, mixed with suitable vehicles.Type: GrantFiled: September 3, 2014Date of Patent: April 17, 2018Assignee: ABIOGEN PHARMA S.P.A.Inventors: Sergio Rosini, Silvia Trasciatti
-
Patent number: 7968748Abstract: A process for resolving a compound in racemic form comprising the following steps is described: a) reacting a compound in racemic form with a resolving agent, b) forming a diastereoisomeric complex of the resolving agent and an enantiomer of interest, c) separating the enantiomer of interest from the obtained diastereoisomer, wherein such a process is characterized in that said resolving agent is a compound of Formula (I). A diastereoisomeric complex between the resolving agent of Formula (I) and the enantiomer of interest is also described. The process according to the invention allows acid and basic racemic mixtures to be separated.Type: GrantFiled: February 1, 2007Date of Patent: June 28, 2011Assignee: Abiogen Pharma S.p.A.Inventors: Elio Napolitano, Rita Fiaschi, Chiara Bechini, Gabriella Brunetto
-
Publication number: 20110039902Abstract: A process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one is described, comprising the step of reacting 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydroben-zo[d]isoxazol-4-one with oxalic acid in one or more solvents, wherein at least one solvent is a solvent having a carbon atom number of from 3 to 6, said solvent being non-halogenated and having a dielectric constant ? within the range from 4 to 25. The process of the invention enables a co-crystal comprising 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one and oxalic acid to be obtained.Type: ApplicationFiled: April 23, 2009Publication date: February 17, 2011Applicant: ABIOGEN PHARMA S.P.A.Inventors: Fabio Neggiani, Elio Napolitano, Simone Basagni, Barbara Politi